95218-34-1

Basic information

• Product Name: N-(2,4-Dimethoxybenzyl)glycine ethyl ester
• Synonyms: Ethyl 2-(2,4-dimethoxybenzylamino)acetate;[(2,4-Dimethoxybenzyl)amino]acetic acid ethyl ester;N-(2,4-Dimethoxybenzyl)glycine ethyl ester
• CAS NO: 95218-34-1
• Molecular Formula: C₁₃H₁₉NO₄
• Molecular Weight: 253.29
• Mol File: 95218-34-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 353.8 °C at 760 mmHg
• Flash Point: 167.8 °C
• Appearance: /
• Density: 1.091
• Vapor Pressure: 3.5E-05mmHg at 25°C
• Refractive Index: 1.501
• CAS DataBase Reference: N-(2,4-Dimethoxybenzyl)glycine ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-Dimethoxybenzyl)glycine ethyl ester(95218-34-1)
• EPA Substance Registry System: N-(2,4-Dimethoxybenzyl)glycine ethyl ester(95218-34-1)

Safety Data

• Hazardous Substances Data: 95218-34-1(Hazardous Substances Data)

Usage

General Description

N-(2,4-Dimethoxybenzyl)glycine ethyl ester is a chemical compound that is often used in the field of organic synthesis. It is a derivative of glycine, an amino acid, and is typically produced through the reaction of 2,4-dimethoxybenzyl chloride with glycine ethyl ester. N-(2,4-Dimethoxybenzyl)glycine ethyl ester has been studied for its potential use in pharmaceutical applications, as it may have therapeutic effects on the central nervous system. Additionally, it has also been investigated for its potential use as a building block in the synthesis of more complex organic molecules. Overall, N-(2,4-Dimethoxybenzyl)glycine ethyl ester is a versatile chemical that has potential applications in both the pharmaceutical and organic synthesis industries.

InChI:InChI=1/C13H19NO4/c1-4-18-13(15)9-14-8-10-5-6-11(16-2)7-12(10)17-3/h5-7,14H,4,8-9H2,1-3H3

Upstream product

• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 623-33-6 glycine ethyl ester hydrochloride 
• 20781-20-8 2,4-Dimethoxybenzylamine 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1194060-93-9 ethyl 12-chloro-8-[(2,4-dimethoxyphenyl)methyl]-9-oxo-2,4, 8-triazatricyclo[8 .4.0.0²,⁶]tetradeca-1⁽¹⁴⁾,3,5,10,12-pentaene-5-carboxylate 
• 20839-79-6 (2,4-dimethoxy-benzylamino)-acetic acid 
• 1455091-64-1 4-(2,6-difluorophenoxy)-2-{[(2,4-dimethoxybenzyl)(ethoxycarbonylmethyl)amino]methyl}benzoic acid ethyl ester 
• 1455092-20-2 4-(2-chloro-5-fluorophenoxy)-2-{[(2,4-dimethoxybenzyl)(ethoxycarbonylmethyl)amino]methyl}benzoic acid ethyl ester 
• 1455091-81-2 2-{[(2,4-dimethoxybenzyl)(ethoxycarbonylmethyl)amino]methyl}-4-(pyridin-3-yloxy)benzoic acid ethyl ester 
• 1455091-74-3 4-(4-chloro-3-fluorophenoxy)-2-{[(2,4-dimethoxybenzyl)(ethoxycarbonylmethyl)amino]methyl}benzoic acid ethyl ester 
• 1455091-61-8 4-bromo-2-{[(2,4-dimethoxybenzyl)(ethoxycarbonylmethyl)amino]methyl}benzoic acid ethyl ester 
• 1403660-73-0 ethyl 2-((R,4E,6E)-N-(2,4-dimethoxybenzyl)-6-methyl-3-oxo-8-((1R,3R,4S,5R)-1,4,8-tri-methyl-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)nona-4,6-dienamido)acetate 
• 1219943-59-5 1-(2,4-dimethoxybenzyl)-4-hydroxy-3-phenyl-1H-pyrrol-2(5H)-one 
• 1219943-61-9 1-(2,4-dimethoxybenzyl)-4-hydroxy-3-(3-methoxyphenyl)-1H-pyrrol-2(5H)-one 
• 1219943-62-0 3-(4-bromophenyl)-1-(2,4-dimethoxybenzyl)-4-hydroxy-1H-pyrrol-2(5H)-one 
• 1219943-63-1 1-(2,4-dimethoxybenzyl)-3-(4-fluorophenyl)-4-hydroxy-1H-pyrrol-2(5H)-one 
• 1219943-60-8 1-(2,4-dimethoxybenzyl)-4-hydroxy-3-(4-methoxyphenyl)-1H-pyrrol-2(5H)-one 
• 1219943-64-2 1-(2,4-dimethoxybenzyl)-4-hydroxy-3-(2-thienyl)-1H-pyrrol-2(5H)-one 

Relevant articles and documents

AKT INHIBITOR

The present invention discloses an AKT inhibitor, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the use thereof in prevention and/or treatment of a disease mediated by AKT protein kinase.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraries

The design, synthesis and decoration of six small molecule libraries is described. Each library was inspired by structures embedded in the framework of specific alkaloid natural products. The development of optimised syntheses of the required molecular scaffolds is described, in which reactions including Pd-catalysed aminoarylation and diplolar cycloadditions have been exploited as key steps. The synthesis of selected exemplar screening compounds is also described. In five cases, libraries were subsequently nominated for production on the basis of the scope and limitations of the validation work, as well as predicted molecular properties. In total, the research has led to the successful synthesis of >2500 novel alkaloid-like compounds for addition to the screening collection (the Joint European Compound Library, JECL) of the European Lead Factory.